Our mission
To change the fate of children with neuroblastoma through funding groundbreaking worldwide research, raising awareness, and enhancing the practice of neuroblastoma treatment.
Since neuroblastoma represents “only” 8% of childhood cancer, it is not a money maker for the drug companies to support. Sadly, money in the world we live in, is more important than kids’ lives.
Neuroblastoma is considered an orphan disease – the “Valley of Death” for physician scientists, where discoveries are made, tool compounds are developed, but there are no means to get these drugs to kids.
A large part of the funding for neuroblastoma treatments comes from private institutions, generous donors, and families of children with neuroblastoma. That’s why we exist.
Research First
We prioritize funding cutting-edge research that shows real promise in fighting neuroblastoma.
Global Impact
Neuroblastoma affects children worldwide. Our mission knows no borders.
Community
We build a supportive community for families affected by neuroblastoma.
Accountability
We are committed to responsible stewardship of every donation.
What We Do
Fund Research
We find the best and promising research in the world that lacks funding, and support them to find the breakthrough and implementation.
Raise Awareness
We raise awareness to neuroblastoma within doctors and parents, to support early diagnosis, which can literally save kids' lives.
Enable Collaboration
We enhance neuroblastoma practice in Israel through international collaboration among medical professionals and institutions.
We will find the breakthrough and change the fate of kids with neuroblastoma worldwide!
RESEARCH & AWARENESS
Funding cutting-edge neuroblastoma research, hosting expert-led webinar sessions, and driving early detection awareness worldwide through International Neuroblastoma Awareness Day.
FAMILY & COMMUNITY
Connecting families navigating neuroblastoma with resources, peer support, and a global community of advocates who understand what they’re going through.
GRASSROOTS ACTION
Empowering ambassadors and volunteers around the world to raise awareness in their communities, from lemonade stands to local advocacy campaigns.
Shir for Life is a registered 501(c)(3) nonprofit organization. All donations are tax-deductible.
Founder & Executive Director
Einat Dado Baralia founded Shir for Life in memory of her son, Shir, who passed away from neuroblastoma at the age of two. What began as one family’s personal story of devastating loss has grown—under her leadership—into a global movement funding research, supporting families, enhancing neuroblastoma practice and advocating for change in how childhood cancer is understood and treated.
Since establishing Shir for Life, Einat has led initiatives that connect and strengthen the global neuroblastoma community, including the creation of International Neuroblastoma Awareness Day and an ongoing Global Webinar Series that brings together experts, researchers, and thousands of parents from around the world.
Einat continues to guide Shir for Life with compassion and determination, working to ensure that every child diagnosed with neuroblastoma has access to better treatments, stronger support, and a more hopeful future.
Board of Directors
Talia has a Bachelors of Science from NYU’s Stern School of Business. Talia’s extensive career in fashion spans design, manufacturing and merchandising throughout the menswear field. Unfortunately, Neuroblastoma has touched too many of her close friends and she is passionate about helping to stop this aggressive cancer in its tracks. Talia resides in Manhattan with her children and husband and is very active in the local community.
Alan Roemer is an entrepreneurial life sciences executive and board member who has launched multi-billion-dollar biotechnology companies, resulting in nine new drug approvals. He has raised approximately $2 billion in private and public capital, led five IPOs, and guided numerous strategic partnerships. Alan currently serves as Chairman of the Board of IN8bio (Nasdaq:INAB), Trustee and Treasurer of the Helene Fuld College of Nursing, and advisor to several biotechnology ventures. He is passionate about leveraging his experience to advance innovative treatments for children and families facing neuroblastoma. Alan holds a BSBA from Georgetown University, and MBA and MPH degrees from Emory University.
Sharon has spent the past two decades advising corporations and nonprofit organizations on strategy, operations, and growth. Currently an operating executive with KKR focused on driving transformation for portfolio companies. Sharon was previously a Managing Director and Partner at the Boston Consulting Group’s Tel Aviv office and head of the social impact practice in Israel. Beyond a professional commitment to purposeful growth, Sharon is deeply connected to Shir for Life’s mission—both as someone profoundly moved by Shir’s story and his family’s strength, and as a survivor who understands the importance of hope, community, and resilience. Joining the board is both a personal and professional calling: a chance to help expand the organization’s reach, amplify its message, and support families facing cancer with the same courage and compassion that inspired its founding.
SCIENTIFIC BOARD
Francesca Del Bufalo, MD, PhD
Ospedale Pediatrico Bambino Gesù
Rome, Italy
Dr. Del Bufalo is a physician-scientist with interest in childhood malignancies, tumor immunology, immunotherapy and hematopoietic stem cell transplantation. She participated in the preclinical and clinical development of the academic clinical trials with CAR-T cells at OPBG. In particular, she coordinated 2 studies on different CD9-CAR T cell platforms for the treatment of children with relapsed/refractory (r/r) BCP-ALL and the phase I/II study to test GD2-CART01 in children with r/r neuroblastoma. She is the PI of a research project to test donor-derived CAR T cells for the treatment of children/young adults with BCP-ALL. She managed the activation and conduction of the phase I clinical trial on CD7-CART.PEBL for the treatment of children/young adults with r/r T-ALL (PI Prof. Franco Locatelli). She is the new chair of the European iBFM Resistant Disease Committee and President of the Young Investigators Section of the scientific technical committee of the Italian Ministry of Health.
Daniel Morgenstern, MB BChir, PhD
Staff Physician, Solid Tumour Program, Haematology/Oncology; Director of New Agent and Innovative Therapies Program; Medical Director of Oncology and BMT/CT Clinical Trials Support Unit; Head of Clinical Trials, The Hospital for Sick Children; Associate Scientist, Translational Medicine, SickKids Research Institute; Associate Professor, Department of Pediatrics, University of Toronto
Daniel Morgenstern is a Staff Oncologist at Hospital for Sick Children, Toronto and Associate Professor at the University of Toronto. He originally trained and worked in the UK, primarily at Great Ormond Street Hospital in London where he was clinical lead for the neuroblastoma. Dr. Morgenstern moved to SickKids, Toronto in 2016 as Director of the New Agent and Innovative Therapy (NAIT) and Therapeutic mIBG Programs, and co-lead of the neuroblastoma service. He is also Medical Director of the Oncology/BMT Clinical Trials Support Unit, co-chair of the C17 Council Developmental Therapeutics Committee and since September 2025, Head of Clinical Trials at Hospital for Sick Children. Dr. Morgenstern’s clinical activities are focussed on neuroblastoma and solid tumour patients participating in early phase clinical trials. His research interests are in early phase trials and, in particular, the use of immune checkpoint inhibitors in paediatric cancers and the development of precision medicine approaches for paediatric solid tumours.
Powered by
